TickerFacts.

Akebia Therapeutics, Inc. (AKBA): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Older than the company's other figures. The latest EBITDA is for the year ended 2022-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$79.12M
Year ended 2022-12-31
2014-12-31: -$37.89M2015-12-31: -$61.42M2016-12-31: -$136.16M2017-12-31: -$76.06M2018-12-31: -$177.26M2019-12-31: -$284.04M2020-12-31: -$375.75M2021-12-31: -$262.57M2022-12-31: -$79.12M-$79.12M
2014-12-31 EBITDA (USD) 2022-12-31
Period endedEBITDAChange YoYSource filing
2022-12-31-$79.12Mn/m2024-03-14, From 2022-01-01
2021-12-31-$262.57Mn/m2023-08-28, From 2021-01-01
2020-12-31-$375.75Mn/m2023-08-28, From 2020-01-01
2019-12-31-$284.04Mn/m2022-03-01, From 2019-01-01
2018-12-31-$177.26Mn/m2021-02-25, From 2018-01-01
2017-12-31-$76.06Mn/m2020-03-12, From 2017-01-01
2016-12-31-$136.16Mn/m2019-03-26, From 2016-01-01
2015-12-31-$61.42Mn/m2018-03-12, From 2015-01-01
2014-12-31-$37.89Mn/a2017-03-06, From 2014-01-01